GlobeNewswire

Komet Reports 185 and 149.6 g/t Au from Grab Samples within the Guiro Mine

Dela

UEBEC CITY, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Komet Resources Inc. ("Komet" or the "Company") is pleased to announce a gold discovery 4km from the Guiro mine and the development of a new unmined shoot at the mine.

New Gold Zone

Komet geologists' verification of three 40m deep gold diggers' shafts, located about 4km northeast of the Guiro mine, revealed a quartz vein with a true width of 1.5m, oriented east-west, with a northward dip of 60 degrees. The vein has the same mineralogical composition and the same host rock limonitic alteration from weathering as the Guiro mine vein.

Sampling was carried out by Komet geologists in sealed bags directly from grab samples brought to surface by the gold diggers. The samples are random samples (3 grabs takes per composite sample). These grab samples are indicative but not representative of the grade of the gold structure.

Table of results of the grab samples:

Samples Description Au g/t
201 806 870 White quartz vein with black minerals bands, bearing limonite, hematite and pyrite 47.0
201 806 871 White quartz vein with black minerals bands, bearing limonite, hematite and pyrite 7.08
201 806 872 White quartz vein with black minerals bands, bearing limonite, hematite and pyrite with rare banded hematite 13.9
201 806 873 White quartz vein with hematitic alteration and disseminated hematite and pyrite 12.4
201 806 874 White quartz vein with hematite stringers with disseminated limonite and pyrite 9.89

New underground zone at the Guiro mine.

During the development in the western sector of the mine (see the October 23, 2017 press release), the Level 3 west gallery intercepted the junction where the 210/80 oriented shear cuts the Guiro vein (270/60).

In this sector the Guiro vein is hardly perceptible due to the shear that displaced the main structure. However, the operators noted the presence of thin centimetric quartz veins with gold mineralization, grading up to 120 g/t over 1.2m obtained from jackleg drill holes.

Table of the best results over 1.2m (true width) from jackleg drill holes:

Samples Au g/t
201 706 564 120.0
201 706 574 10.1
201 706 575 31.8
201 706 581 110.0

In order to better characterize this zone, several grab samples were taken from the roof, the wall and the sludge surrounding these thin chloritized white-pink quartz veins.

Summary of the best results of the grab samples:

Samples Au g/t
201 706 611 72.5
201 706 612 47.0
201 706 614 17.0
201 706 615 22.7
201 706 616 11.7
201 706 617 14.7
201 706 618 149.6
201 706 621 17.6
201 706 646 13.4
201 706 647 82.7
201 706 650 63.1
201 706 651 60.3
201 706 635 12.6
201 706 641 27.7
201 706 642 26.8

 

Samples Au g/t
201 706 655 26.9
201 706 658 185.0
201 706 661 13.5
201 706 667 10.5
201 706 668 11.6
201 706 669 52.3
201 706 670 12.5
201 706 672 67.4
201 706 677 12.6
201 706 680 50.6
201 706 684 16.5
201 706 687 13.9
201 706 692 16.5
201 706 693 14.5

The chimney to which the current development of level 3 is oriented, theoretically lies 25m farther west and has already been intercepted by the Gu2015dd04, 06, 32 and 35 diamond drill holes who show metric grades reaching 31.1g/t Au (see the September 10, 2015, press release for more details).

Table of the survey intercepting the chimney:

Survey From (m) To (m) g/t Au Span (m) True width (m)
Gu2015dd04 125.33 127.28 5.81 1.95 1.69
Gu2015dd06 80.60 83.40 2.05 2.80 2.42
Gu2015dd32 149.00 149.66 8.73 0.66 0.57
Gu2015dd35 105.45 106.80 31.1 1.35 1.17

This chimney is at least 50m wide at level 3 and continues to level 2 and 4 and should have, between these levels, a 60x50x2m size.

Guiro Mine Exploration

The sinistral offset of the Guiro structure, along the 210-degree shear in the west section of the mine, implies that this type of displacement might be present in the eastern sector, involving the displacement of the Guiro vein to the north and thus opening up new exploration targets northeast of the Guiro mine.

Mr André Gagné, president and CEO declare: "After a discovery south to the Guiro vein (see the may 25, 2017 press release), we now have a new vein to the north which is also similar to the Guiro vein. The exploration activities will hence be intensified in the next few weeks; it appears that the historical exploration data is getting confirmed."

The grab samples assays reported were obtained by standard 30 grams fire-assaying-AA finish or gravimetric finish at the Company's mine site laboratory. Quality Assurance/Quality Control and interpretation of results is performed by qualified persons employing a QA/QC program consistent with NI 43-101 and industry best practices, including the introduction of standards or blanks with every batch of 3 samples analyzed.

The diamond drill holes samples from 2015 were analyzed by the SGS Lab in Ouagadougou using fire assay followed by atomic absorption spectrometry.

More information about the corporation is available at: http://kometgold.com.

Investors relations and information: André Gagné, President and CEO 581-300-1666 / a.gagne@kometgold.com  / Skype: andregagne11

Jacques Marchand, P.Eng. P.Geo., is the Qualified Person who has reviewed this news release and is responsible for the geological information presented herein.

Forward-Looking Statements

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains statements that may constitute "forward-looking information" or "forward-looking statements" as set out within the context of security law. This forward-looking information is subject to many risks and uncertainties, some of which are beyond Komet's control. The actual results or conclusions may differ considerably from those that have been set out, or intimated, in this forward-looking information. There are many factors which may cause such disparity, especially the instability of metal market prices, the results of fluctuations in foreign currency exchange rates or in interest rates, poorly estimated resources, environmental risks (stricter regulations), unforeseen geological situations, unfavorable extraction conditions, political risks brought on by mining in developing countries, regulatory and governmental policy changes (laws and policies), failure to obtain the requisite permits and approvals from government bodies, or any other risk relating to mining and development. There is no guarantee that the circumstances anticipated in this forward-looking information will occur, or if they do occur, how they will benefit Komet. The forward-looking information is based on the estimates and opinions of Komet's management at the time of the publication of the information and Komet does not assume any obligation to make public updates or modifications to any of the forward-looking statements, whether as a result of new information, future events, or any other cause, except if it is required by securities laws.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ccdd8280-c01e-4a86-a03b-ce1c316c11b1




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Komet Resources Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum